Advertisement

CAR-T Cell Expansion in a Xuri Cell Expansion System W25

  • Trevor A. SmithEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 2086)

Abstract

Cell expansion is typically a long and labor-intensive step in CAR-T cell manufacture. The Xuri Cell Expansion System (CES) W25 semiautomates this step while functionally closing the process. Cells for autologous or allogeneic cell therapies are cultured inside a single-use Xuri Cellbag™ bioreactor. Wave-induced agitation, performed by a rocking Base Unit, transfers gas and mixes the culture. The integral UNICORN™ software allows customization of culture conditions and media perfusion schedules. Culture volumes can range from 300 mL to 25 L, making the Xuri CES W25 system suitable for both scale-up and scale-out manufacturing processes. CAR-T cell therapies have been successfully generated using the Xuri CES W25 system, which reduces manual labor compared with static culturing methods. This chapter details how to initiate a culture, install the Xuri CES W25, and install a 2 L Cellbag bioreactor. Protocols on inoculation, monitoring, and sampling are also outlined in this chapter.

Key words

T lymphocytes CAR-T cells Immunotherapy Cell therapy Gene therapy Bioreactor Autologous Allogeneic 

Notes

Acknowledgments

The author thanks Matt Sherman, PE for providing the 2 L Cellbag bioreactor line drawing in Fig. 2, the Cellular Biology team at the GE Global Research Center for their continued mentorship, and the Centre for Commercialization of Regenerative Medicine for their persistence in expanding the applications of the Xuri Cell Expansion System W25.

References

  1. 1.
    Vormittag P, Gunn R, Ghorashian S, Veraitch F (2018) A guide to manufacturing CAR T cell therapies. Curr Opin Biotechnol 53:164–181CrossRefGoogle Scholar
  2. 2.
    Janas ML, Nunes C, Marenghi A, Sauvage V, Davis B, Bajas A, Burns A (2015) Perfusion’s role in maintenance of high-density T-cell cultures. Bioprocess Int 13(1):18–26Google Scholar
  3. 3.
    Areman EM, Loper K (2009) Cellular therapy: principles, methods, and regulations. AABB Press, BethesdaGoogle Scholar
  4. 4.
    Hollyman D, Stefanski J, Przbylowski M, Bartido S, Borquez-Ojeda O, Taylor C et al (2009) Manufacturing validation of biologically functional T cells targeted to CD19. J Immunother 32(2):169–180CrossRefGoogle Scholar
  5. 5.
    Sadeghi A, Pauler L, Anneré C, Friberg A, Brandhorst D, Korsgren O, Totterman TH (2011) Large-scale bioreactor expansion of tumor-infiltrating lymphocytes. J Immunol Methods 364:94–100CrossRefGoogle Scholar
  6. 6.
    Healthcare GE (2018) A semi-automated, high-purity process for NK cell manufacturing in a rocking bioreactor. (KA4771180618PO). General Electric, Boston, MAGoogle Scholar
  7. 7.
    Davis BM, Loghin ER, Conway KR, Zhang X (2018) Automated closed-system expansion of pluripotent stem cell aggregates in a rocking-motion bioreactor. SLAS Technol 23(4):364–373.  https://doi.org/10.1177/2472630318760745CrossRefPubMedGoogle Scholar
  8. 8.
    Kokaji AI, Sun CA, Ng V, Lam BS, Clark SJ, Woodside SM, Eaves AC, Thomas TE (2016) Scalable human T cell isolation, activation and expansion using EasySep™ and ImmunoCult™ by STEMCELL Technologies. Eur J Immunol 46(Suppl 1):119–120Google Scholar
  9. 9.
    Brentjens RJ et al (2011) Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118(18):4817–4828CrossRefGoogle Scholar
  10. 10.
    Iyer RK, Bowles PA, Howard K, Dulgar-Tulloch A (2018) Industrializing autologous adoptive immunotherapies: manufacturing advances and challenges. Front Med 5(150):1–9Google Scholar
  11. 11.
    GE Healthcare (2016) T cell expansion with Xuri™ systems: isolation and cultivation protocol (document number 29112375 revision AB). General Electric, Boston, MAGoogle Scholar
  12. 12.
    Golubovskaya V, Wu L (2016) Different subsets of T cells, memory, effector functions, and CAR-T immunotherapy. Cancers (Basel) 8(3):36CrossRefGoogle Scholar
  13. 13.
    Xu W, Larbi A (2017) Markers of T cell senescence in humans. Int J Mol Sci 18(8):1742CrossRefGoogle Scholar
  14. 14.
    Ismail R, Janas M, Stone S, Marenghi A, Sauvage V (2013) Expansion of T-cells using the Xuri™ cell expansion W25 and WAVE bioreactor™ 2/10 system. In: Developments in cell expansion for cell processing. GE Healthcare Life Sciences, Chicago, Illinois. https://www.gelifesciences.com/solutions/cell-therapy/knowledge-center/resources/developments-in-cell-expansion. Accessed 22 May 2018Google Scholar
  15. 15.
    Gee AP (2018) GMP CAR-T cell production. Best Pract Res Clin Haematol 31(2):126–134CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Authors and Affiliations

  1. 1.Cell and Gene Therapy TeamGE HealthcareMarlboroughUSA

Personalised recommendations